fda crackdown on compounded semaglutide is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified On February 2, 2026, Pope

Financial Times reported this week that Lilly and Novo, the manufacturers of all four GLP-1 drugs commonly used for obesity therapy, are spending $3.5 billion this year to purchase smaller companies with promising anti-obesity therapies

After injecting, release the skin fold and withdraw the needle

New iterations have been rolling out ever since

However, telehealth does not make investigational drugs like retatrutide available outside a clinical trial

As always, Im slow to recommend or adopt new medications, with a 7 year rule

For example, supplements that support sleep quality, stress response, blood sugar balance, or muscle health may help make weight loss efforts more effective and sustainableparticularly when used alongside clinician-guided treatment